In an era obsessed with early detection, Rohin Francis delivers a provocative counter-narrative: the medical pursuit of "fake disease" is causing more harm than the illnesses it seeks to prevent. This piece cuts through the comforting rhetoric of "better safe than sorry" to expose how aggressive screening programs, driven by fear and flawed statistics, are subjecting asymptomatic people to unnecessary surgeries, radiation, and trauma. For busy professionals navigating a complex healthcare landscape, Francis's argument that "disease from the Latin literally meaning without ease is not present if the pathology is not causing any symptoms" offers a crucial, if unsettling, lens on modern medicine.
The Illusion of Saving Lives
Francis opens by dismantling the emotional marketing of full-body scans and "well man" checkups, which he argues rely on "scare mongering" to convince healthy people they are at fault for not paying attention to their health. He illustrates this with the case of "Kevin Hart," a man who undergoes a cardiac CT scan for a narrowing artery, receives a stent, and suffers complications, only to have his life unchanged in terms of longevity. Francis writes, "we know that in fact the likely outcome of them undergoing those initial tests is that they've been harmed more than they've benefited." This reframing is powerful because it shifts the focus from the technical success of finding a problem to the actual clinical outcome for the patient.
The author argues that for stable, asymptomatic patients, interventions like stents do not prolong life or prevent heart attacks, a stark contrast to their life-saving utility in patients experiencing active symptoms. He notes, "don't get me wrong for unstable patients people having chest pain people having heart attacks stents are life saving... but not for patients like Kevin." This distinction is vital, yet it is often blurred in public discourse where the mere presence of a blockage is treated as a ticking time bomb requiring immediate resolution.
"The correlation coefficient between five-year survival and death for the most common cancers was looked at and it was zero and that's really saying something there's no link between five-year survival and how many people are dying from a disease which is of course the thing that any sufferer cares about."
Francis uses this statistical reality to attack the metric most often used to sell screening: five-year survival rates. He explains how "lead time bias" creates the illusion of success by simply diagnosing a condition earlier without actually delaying death. As he puts it, "if you diagnose someone here even though you're dying at the exact same time you've not helped them in any way their survival time from diagnosis is better simply because you've diagnosed them earlier." This is a sophisticated point that challenges the intuitive belief that earlier is always better, forcing readers to question the very data they are told to trust.
The Epidemic of Overdiagnosis
The commentary then pivots to the concept of "overdiagnosis," which Francis defines as the detection of abnormalities that would never have caused symptoms or death. He points to the rising number of cancer diagnoses over the last forty years, juxtaposed against stable death rates, as evidence that we are increasingly finding "fake disease." He writes, "either our treatments are getting better at exactly the same rate as the increase in cases or we're diagnosing things that aren't causing any harm aka fake disease." This observation is particularly striking in the context of lung cancer screening, where a major trial recently concluded that screening resulted in "more scans more invasive tests and more treatments like chemotherapy but no difference in death rate."
Francis employs a visual analogy of cancer growth trajectories to explain why screening inevitably catches slow-growing, harmless lesions alongside aggressive ones. He describes a scenario where a patient dies "with but not from" a slow-growing cancer, noting that "if you look down a microscope the cells have all the hallmarks of cancer but it's not cancer in the way that you or I or society understands it." This distinction is critical for understanding why a positive biopsy does not always equate to a life-threatening condition. Critics might note that distinguishing between a harmless lesion and a dangerous one is often impossible in real-time, leading to the current "treat all" approach. However, Francis argues that this uncertainty is precisely why the default should be caution, not aggressive intervention.
"Disease from the Latin literally meaning without ease is not present if the pathology is not causing any symptoms nor adversely affecting the person's life so this is what I mean by fake disease treating these will not only not help the patient but may even harm them which is the one thing that doctors are definitely not supposed to do."
The author also addresses the role of incidental findings, or "incidentalomas," which are becoming more common as imaging technology becomes more sensitive. He cites the example of a cardiac MRI, which scans the heart but also captures surrounding organs like the thyroid, leading to unexpected findings that trigger a cascade of further testing. Francis notes that "the rate of incidentalomas is soaring," creating a feedback loop of anxiety and medicalization for healthy individuals. This section highlights a systemic issue where technological capability outpaces clinical wisdom, turning incidental findings into a source of iatrogenic harm.
The Power of Anecdote vs. Data
Francis concludes by addressing the emotional weight of personal stories, which often override statistical evidence in public perception. He acknowledges the sincerity of celebrities who credit screening with saving their lives but warns that "the great success in these ducks like a quack videos I often talk about the power of anecdote normally is a problematic thing." He argues that while individual stories are compelling, they can obscure the reality that many people undergo screening and find nothing, or worse, find something that leads to unnecessary treatment. He writes, "if screening is misunderstood by many in the medical profession then it's unfair to expect anything different from non medics." This admission of professional confusion adds credibility to his argument, suggesting that the problem is not just public misunderstanding but a systemic issue within medicine itself.
"If you have a hundred patients with the particular cancer in five years time 50% of them are alive that's a survival rate of 50% but with screening you may pick up another hundred who have fake disease and now you've got 200 patients to start with in five years time fifty are still dead you haven't prevented a single death but you can immediately claim that survival rate is now 75%."
This final illustration of how screening can artificially inflate survival rates without reducing mortality is the piece's most damning indictment of current practices. It exposes the mathematical trickery that allows the medical industry to claim success even when patient outcomes remain unchanged. Francis's argument is that until we stop using misleading metrics and start focusing on mortality rates and quality of life, we will continue to perpetuate an epidemic of "fake disease."
Bottom Line
Rohin Francis's argument is a necessary corrective to the uncritical enthusiasm for early detection, grounding the debate in hard data and the reality of patient harm. Its greatest strength lies in its ability to translate complex statistical concepts like lead time bias and overdiagnosis into accessible, compelling narratives. However, the piece's biggest vulnerability is the difficulty of implementing a "wait and see" approach in a medical culture and legal system that often demands action. Readers should watch for how policy shifts toward risk-based screening rather than population-wide mandates, as this may be the only path forward that balances early detection with the prevention of unnecessary harm.